Radiopharmaceuticals for targeted radiotherapy

Radiation Protection Dosimetry

Volumn 116, Issue 1-4, 2005, Pages 601-604

  Marques, Fernanda ^a   Paulo, António ^a   Campello, Maria Paula ^a   Lacerda, Sara ^a   Vitor, Rute Filipe ^a   Gano, Lurdes ^a   Delgado, Rita ^b   Santos, Isabel ^a  

^a INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLOTRIDECANE 1,4,7,10 TETRAACETIC ACID; 1,4,8,11 TETRAAZACYCLOTETRADECANE 1,4,8,11 TETRAACETIC ACID; ANTHRACENE DERIVATIVE; CHELATING AGENT; CYCLAM DERIVATIVE; HOLMIUM; HOLMIUM 166; INTERCALATING AGENT; LOSOXANTRONE; POLYAMINE DERIVATIVE; PYRAZOLYLDIAMINE DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM COMPLEX; SAMARIUM 153; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ARTICLE; BETA RADIATION; CANCER CELL; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPLEX FORMATION; DNA DAMAGE; DRUG BINDING; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; ISOTOPE LABELING; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DNA, NEOPLASM; HUMANS; ISOTOPE LABELING; NEOPLASMS; RADIATION DOSAGE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 31544473459     PISSN: 01448420     EISSN: None     Source Type: Journal    
DOI: 10.1093/rpd/nci251     Document Type: Article

References (13)

1. Hoefnagel, C. A. Radionuclide cancer therapy. Ann. Nucl. Med. 12, 61-70 (1998).
2. Volkert, W. A., Goeckeler, W. F., Ehrhardt, G. J. and Ketring, A. R: Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med. 32, 174-185 (1991).
3. Neves, M., Kling, A. and Lambrecht, R. M. Radionuclide production for therapeutic radiopharmaceuticals. Appl. Radiat. Isot. 57, 657-664 (2002).
4. Liu, S. and Edwards, D. S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug. Chem. 12, 7-34 (2001).
5. Froidevaux, S. and Eberle, A. N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66, 161-183 (2002).
6. de Jong, M., Kwekkeboom, D., Valkema, D. R. and Krenning, E. P. Radiolabelled peptides for tumour therapy: Current status and future directions. Eur. J. Nucl. Med. Mol. Imaging 30, 463-469 (2003).
7. Arnaud-Neu, F., Delgado, R. and Chaves, S. Critical evaluation of stability constants and thermodynamic functions of metal complexes of crown ethers. Pure Appl. Chem. 75, 71-102 (2003).
8. Hofer, K. G. Biophysical aspects of Auger processes. Acta Oncol. 39, 651-657 (2000).
9. Mariani, G., Bodei, L., Adelstein, S. J. and Kassis, A. I. Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J. Nucl. Med. 41, 1519-1521 (2000).
10. 99mTc. Eur. J. Nucl. Med. 30, S199 (2003).
11. Vogel, C. L. and Nabholtz, J. M. Monotherapy of metastatic breast cancer: A review of newer agents. Oncologist 4, 17-33 (1999).
12. + moiety. J. Chem. Soc. Dalton Trans. 24, 4714-4719 (2002).
13. +. J. Am. Chem. Soc. 123, 3135-3136 (2001).